Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 January, 2019 22:11 IST
Glenmark Pharm quarterly earnings fall 17.5%
Source: IRIS | 30 May, 2018, 10.54AM
Comments  |  Post Comment

Earnings per share for the quarter stood at Rs 5.37, registering 17.51% decline over previous year period.

''While FY 2018 was a challenging year mainly on account of pricing pressure in the U.S., our other key markets like Europe and India performed well on the back of new product launches. Even though we expect pricing pressure to persist, we are glad that FY 2019 has started on a positive note for us with approvals for some interesting products in the U.S.,'' said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals. (Q,N,C,F)* He further added, ''We recently filed our first New Drug Application (NDA) for Ryaltris in the U.S, which is a milestone in Glenmark's journey and marks our first step towards the transition to a specialty and innovative drugs company. We believe our strong R&D pipeline of novel assets will help propel growth in the long run.''

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Ratnamani Metals & Tubes receives order worth Rs 2 bn - 18-Jan-2019 15:59
Aurobindo Pharma to acquire portfolio of oncology injectables products - 18-Jan-2019 13:47
Reliance Ind Q3 earnings up 8.8%; GRM's at USD 8.8/bbl - 18-Jan-2019 13:08
Announcement under Regulation 30 (LODR)-Change in Directorate - 18-Jan-2019 11:14
Zydus receives final approval for Acetazolamide ER capsules - 17-Jan-2019 13:27
OnMobile Global renews its contract with Telefonica Moviles Espana, SAU (Telefonica) - 17-Jan-2019 10:14
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer